NCT07472140 PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
| NCT ID | NCT07472140 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | N.N. Alexandrov National Cancer Centre |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2033-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2025-07-01 with a primary completion date of 2033-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
Eligibility Criteria
Inclusion Criteria: * Age ≥18-≤75 years. * Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Possibility of performing diagnostic laparoscopy or cytoreductive surgery. * Presence of homologous recombination deficiency (HRD). * No contraindications to chemotherapy, or bevacizumab. * Signed informed consent to participate in the study. Exclusion Criteria: * Presence of another active malignant invasive neoplasm. * Pregnancy or lactation period. * Disease progression during treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07472140 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07472140 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07472140 currently recruiting?
Yes, NCT07472140 is actively recruiting participants. Contact the research team at annavladimir@rambler.ru for enrollment information.
Where is the NCT07472140 trial being conducted?
This trial is being conducted at Minsk, Belarus.
Who is sponsoring the NCT07472140 clinical trial?
NCT07472140 is sponsored by N.N. Alexandrov National Cancer Centre. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.